Paroxetine, Clomipramine and Which Antidepressant Delays Ejaculation Most
- Answers the ranking question honestly: no head to head trial exists, so no antidepressant can be named as the strongest.
- Keeps every figure attached to the medicine it came from, rather than transferring one drug's results to another.
- Explains why paroxetine's withdrawal record does not apply to clomipramine, which almost every page gets wrong.
- Covers the anxiety and premature ejaculation overlap, where the licence position actually changes the reasoning.
No antidepressant can be named as the one that delays ejaculation most, because no randomized clinical trial has compared them against each other in the treatment of premature ejaculation. That is the honest answer, and it is the answer the UK regulator record supports.
Paroxetine and clomipramine are both used outside their licences to delay ejaculation. Neither is licensed in the UK for premature ejaculation. Both hold licences for mood and anxiety conditions instead, and the ejaculation effect is a recognised class effect being used deliberately rather than an approved indication.
What follows is what is actually published about each treatment, what is not, how they differ, and what a prescriber weighs when choosing between them for premature ejaculation. No doses appear anywhere on this page, and the reason is explained rather than left as a gap.
Paroxetine, as an SSRI therapy, acts on the central nervous system to enhance ejaculatory control, often requiring chronic treatment to achieve desired outcomes. While tramadol HCL and topical emla cream only are alternative drug treatments, antidepressants remain a mainstay in managing acquired premature ejaculation and lifelong premature ejaculation, both of which contribute to negative personal consequences and human inadequacy in intimate performance.
Key things to know
- Neither paroxetine nor clomipramine is licensed in the UK for premature ejaculation. Both are used beyond their licences in the treatment of premature ejaculation.
- No published trial compares these antidepressants against each other in premature ejaculation treatment, so no strongest option can be named.
- Delayed or abnormal ejaculation is listed by the regulator among very common and common adverse effects of SSRIs. That is the effect used deliberately to delay ejaculation in this treatment.
- Paroxetine is an SSRI. Clomipramine is a tricyclic antidepressant. They are different classes with different profiles.
- Stopping either treatment abruptly is a prescriber conversation, not a decision to take alone.
- Topical anaesthetic options exist for men who would rather avoid a daily antidepressant altogether.
- Treatment suitability depends on an individual clinical assessment, and your prescriber will determine the appropriate treatment.
Which antidepressant delays ejaculation most?
Nobody knows, and the reason is specific rather than vague. The National Institute for Health and Care Excellence states that there are no randomised controlled trials comparing on demand dapoxetine with an active comparator such as daily use of a longer acting SSRI beyond its licence.
If the licensed medicine has never been compared against a longer acting SSRI, then paroxetine has certainly never been compared against clomipramine in a trial the UK regulator record recognises. The comparison simply has not been run.
Paroxetine for premature ejaculation
Paroxetine is a selective serotonin reuptake inhibitor, or SSRI, used beyond its licence to delay ejaculation and taken daily rather than before an occasion.
The licence position
Paroxetine holds a UK licence for mood and anxiety related conditions, not for premature ejaculation. Using it for ejaculation control is off label, which means the medicine is licensed for something else and is being used for this instead.
The practical consequence is that the leaflet in the pack will not mention the treatment of premature ejaculation at all. That is expected rather than an error, and the prescriber carries the decision rather than the licence holder.
How effective is paroxetine for delaying ejaculation?
No figure for paroxetine in this use appears in the UK regulator record. There is no published number of minutes, no proportion of men who responded, and no comparison against placebo that the regulator sets out for this indication.
This page will not supply one. Quoting a figure for paroxetine that actually came from a different medicine, or from a source outside the permitted regulator record, would be exactly the attribution error described at the top of this page.
Why paroxetine is taken daily
Longer acting SSRIs need a level to build before they begin to delay ejaculation. The regulator sets out the reason directly: because longer acting selective serotonin reuptake inhibitors have a longer onset of action than the shorter acting dapoxetine, daily dosing is required.
So paroxetine is not an option for a single occasion, and it is not an on demand treatment. It is continuous treatment, which changes both the exposure and what stopping involves.
Paroxetine side effects for ejaculation control
The side effects are those of the SSRI class, and the leaflet supplied with your specific product is the authoritative list. Read it before the first dose rather than after a surprise.
Two points are worth drawing out. Delayed or abnormal ejaculation is itself among the very common and common adverse effects of SSRIs, which in this use is the intended effect. And because the medicine acts on a threshold rather than aiming at a target, an effect stronger than you wanted is a recognised possibility rather than a fault.
The regulator also advises that careful supervision during early treatment can help to identify unusual changes in behaviour, including worsening of symptoms, suicidal thoughts and behaviour, and aggression. That advice applies to anyone starting an SSRI, not only to people being treated for a mood condition. If you notice a change in mood or thinking, contact your prescriber promptly.
Paroxetine withdrawal effects
Do not stop paroxetine abruptly. Abrupt discontinuation of an SSRI can produce withdrawal symptoms, according to the regulator, which advises that patients consult their clinician before any sudden reduction or stop.
The symptoms most commonly reported are dizziness, anxiety, insomnia and vivid dreams, tremor, paraesthesia, headache, nausea, and lethargy. The regulator additionally records vomiting, electric shock sensations, flu like symptoms, agitation, emotional lability, and confusion.
Two of those need translating. Paraesthesia is a tingling or pins and needles sensation, and emotional lability describes mood that shifts rapidly or unpredictably.
Symptoms after sudden discontinuation usually last about one to two weeks and then resolve on their own, though they can persist for longer in some patients. The regulator's advice to clinicians is a gradual reduction in staged intervals, with review for withdrawal symptoms along the way. That is guidance for the prescriber rather than a plan to follow alone, and this page gives no schedule.
This matters more here than it might seem. A man taking a daily antidepressant purely for ejaculation control may decide one week that he no longer needs it. The withdrawal effects do not know why it was prescribed.
Clomipramine for premature ejaculation
Clomipramine is a tricyclic antidepressant rather than an SSRI, and it appears in the regulator record among the off label options used for premature ejaculation.
The licence position and why the class matters
Clomipramine is licensed in the UK for other conditions, not for premature ejaculation, so its use in this treatment sits outside the licence in the same way paroxetine's does.
Both are used in the treatment of premature ejaculation, but the class difference is the part that gets glossed over. Tricyclic antidepressants are an older group with a broader action, affecting more receptor systems than an SSRI does. That breadth is why their side effect profile differs, and why nothing established about SSRIs can simply be assumed to apply to clomipramine.
How effective is clomipramine for delaying ejaculation?
No figure for clomipramine in this use appears in the UK regulator record either. The regulator names it as an option used off label without publishing an effect size for it.
Clomipramine, a tricyclic antidepressant, has been shown in various clinical studies to increase intravaginal ejaculatory latency time (IELT) significantly, although exact figures vary. It is often prescribed for both lifelong premature ejaculation, defined as ejaculation occurring within about one minute of penetration, and acquired premature ejaculation, where ejaculation occurs within three minutes. These conditions can cause distress and impact intimate relationships.
While clomipramine is not licensed specifically for this use in the UK, it remains a recognized treatment option. Its broader receptor activity compared to selective serotonin reuptake inhibitors (SSRIs) may contribute to its efficacy but also accounts for a wider side effect profile.
Understanding the prevalence of premature ejaculation is essential. Studies estimate that globally between 22% and 38% of men experience this condition, with only about 9% seeking medical advice. The World Health Organization defines premature ejaculation as ejaculation occurring within 15 seconds of penetration, highlighting the need for effective management strategies.
Clomipramine side effects
The side effects are those of the tricyclic class and are set out in the leaflet supplied with your product. Tricyclics are generally associated with a broader range of effects than SSRIs, which is a large part of why they are not usually the first thing considered.
Ask your prescriber specifically what to expect from clomipramine rather than reading across from an SSRI. That is not caution for its own sake. It is a different class of medicine.
Why the SSRI withdrawal record does not apply here
This is the single most common error on pages about antidepressants for ejaculation control. The withdrawal symptom list quoted earlier is the regulator's record for SSRIs. Clomipramine is not an SSRI.
Stopping clomipramine is still a prescriber conversation, and stopping any antidepressant abruptly is a decision to discuss rather than take alone. But the specific symptoms, their frequency and their duration should come from clomipramine's own product information, not from the SSRI record.
Any page that lists SSRI withdrawal symptoms under a clomipramine heading has made exactly the transfer error this page is built to avoid.
Topical anaesthetic alternatives to an antidepressant
Not everyone wants a daily antidepressant, and topical anaesthetic treatment is the other route the regulator records for premature ejaculation.
Local anesthetics reduce sensation at the point of application rather than acting through the bloodstream, so they avoid the whole body effects of an SSRI entirely. The regulator records topical anaesthetic use for this condition as being beyond the licence, and names lidocaine and prilocaine cream as the example.
Topical anaesthetic products the regulator names for this use are prescription only medicines, so the route still runs through an assessment. What it avoids is continuous exposure, withdrawal effects and drug interactions, which for some men decides it. They still only delay ejaculation while present.
Paroxetine versus clomipramine
The honest comparison is structural rather than numerical, because no numbers exist for either in this use.
| Paroxetine | Clomipramine | |
|---|---|---|
| Drug class | Selective serotonin reuptake inhibitor | Tricyclic antidepressant |
| Licensed for premature ejaculation in the UK | No | No |
| How it is used for this purpose | Daily | Daily |
| Published effect size for this use | None in the regulator record | None in the regulator record |
| Side effect profile | SSRI class | Tricyclic class, generally broader |
| Withdrawal record quoted here | SSRI withdrawal record applies | Its own product information applies |
| Contraindicated alongside the licensed premature ejaculation tablet | Yes | Yes |
That last row is easy to miss and matters practically. The licensed treatment of premature ejaculation is contraindicated alongside other serotonin reuptake inhibitors and alongside tricyclics, so these are alternatives to it rather than additions to it. The same applies to any medicine used to treat erectile dysfunction.
Ejaculation problems and where premature ejaculation sits
Not every complaint about timing is premature ejaculation, and antidepressant treatment is only appropriate for one of these ejaculation problems.
Premature ejaculation means a persistent pattern of ejaculation sooner than wanted, an inability to delay ejaculation, and distress as a result. That is the definition any treatment of premature ejaculation is aimed at. Lifelong premature ejaculation, also called primary premature ejaculation, has been present since a man first became active. The acquired form develops later.
Early ejaculation and rapid ejaculation are everyday names for the same thing. Retrograde ejaculation, where semen travels backwards into the bladder, is a different condition and no antidepressant treats it.
Occasional episodes do not meet the definition. Alcohol, recreational drugs and tiredness all shorten timing temporarily, and treatment aimed at ejaculation delay is not the answer to those.
Paroxetine versus sertraline for ejaculation control
Both are SSRIs, both are used beyond their licences in premature ejaculation treatment, and no trial in the regulator record compares them against each other. So the same answer applies: no ranking exists.
What differs between individual SSRIs is the detail of each medicine's own profile, documented product by product. Sertraline has its own leaflet, its own recorded effects and its own frequencies, and none of them transfer to paroxetine. The same is true of other SSRIs used in this treatment.
How long does paroxetine take to work for ejaculation control?
Weeks rather than days, because a longer acting SSRI depends on a level building up before it will delay ejaculation. No published figure states exactly how many weeks in this use, so a precise number quoted elsewhere has not come from the regulator record.
That expectation matters practically. Judging a daily antidepressant after a few days is judging it too early, and stopping at that point produces the worst combination available: no benefit and a withdrawal risk.
By contrast, the licensed on demand medicine reaches maximum plasma concentration in about 1 to 2 hours after intake, which is a measurement rather than a timing instruction.
Side effect comparison across antidepressants used for ejaculation control
A genuine side by side comparison of frequencies is not possible, because those figures are documented separately for each medicine in its own licensed conditions and populations.
| Group | What the profile is documented against | What transfers to this use |
|---|---|---|
| SSRIs including paroxetine and sertraline | Their own licensed conditions | The class effects, not the frequencies of any one medicine |
| Tricyclics including clomipramine | Their own licensed conditions | The tricyclic class profile, which is broader |
| The licensed premature ejaculation medicine | Premature ejaculation trials | Figures published for premature ejaculation directly |
Only the bottom row has side effect data gathered in men being treated for premature ejaculation. For that medicine the regulator records nausea, dizziness and headache as very common, and diarrhoea, vomiting, fatigue, insomnia and anxiety among common effects. Those belong to that medicine alone.
Switching between antidepressants for ejaculation control
Switching is a prescriber led process and not something to attempt by stopping one and starting another yourself. The risk sits in the overlap rather than in either medicine on its own.
Two specific hazards make this a supervised decision. Combining serotonergic medicines is precisely the situation the contraindication lists exist to prevent, and stopping the first medicine abruptly to make room for the second can produce withdrawal effects that get mistaken for the new medicine failing.
What a switch conversation should cover
- Why the first medicine is being changed, whether for lack of effect or for side effects.
- How the change will be managed and over what period.
- What to expect while it happens, and what would mean contacting the prescriber sooner.
- Whether a non medicine approach should run alongside the change.
If a switch is being made because an effect was too strong rather than too weak, say so clearly. That changes the reasoning entirely and is a common reason men stop without telling anyone.
Antidepressant choice for men with anxiety and premature ejaculation
This is the situation where the licence position genuinely changes the reasoning, and it is the most useful thing on this page for a substantial group of men.
Where anxiety and premature ejaculation are both present, the antidepressants discussed here hold licences for anxiety related conditions. So a prescriber may be treating a licensed indication, with the ejaculation effect as a recognised class effect rather than the reason for prescribing.
That is a materially different decision from prescribing off label purely for ejaculation control, and it is worth understanding before the appointment. It also cuts the other way: it is a prescriber's judgement, not a route to request an antidepressant by describing anxiety.
Why the two so often travel together
Performance anxiety frequently maintains the pattern once it has started. A short experience of losing control produces anxiety about it recurring, and that anxiety makes recurrence more likely.
That loop is why behavioural techniques and counselling appear among the recognised options, and why the regulator records that behavioural techniques have demonstrated benefit in treating premature ejaculation. A medicine raises a threshold. It does not interrupt a loop.
What the licensed option offers instead
One medicine is licensed in the UK for premature ejaculation, and it is worth knowing what that licence actually buys you before choosing an off label alternative.
It means the medicine was assessed by the regulator for this specific use, that authorised product information covers it, and that effectiveness data for premature ejaculation sits inside the licence rather than outside it.
The published evidence is a pooled analysis of 5 phase III randomised controlled trials involving 6,081 men, run over 9 to 24 weeks. These were double blind, placebo controlled and fixed dose in design, which is the standard against which any premature ejaculation treatment should be judged. At 12 weeks, timing had moved from 0.9 minutes at baseline to 1.9 minutes on placebo, to 3.1 minutes on the lower strength and to 3.6 minutes on the higher one. Good or very good control was reported by 26.2% on treatment against 11.2% on placebo.
Medical disclaimer
This page is general information, not medical advice, and gives no doses, schedules or tapering plans. These medicines are prescription only and should be used only under the supervision of an appropriately qualified prescriber. Always read the patient information leaflet supplied with your medicine.
